<code id='E556867B2A'></code><style id='E556867B2A'></style>
    • <acronym id='E556867B2A'></acronym>
      <center id='E556867B2A'><center id='E556867B2A'><tfoot id='E556867B2A'></tfoot></center><abbr id='E556867B2A'><dir id='E556867B2A'><tfoot id='E556867B2A'></tfoot><noframes id='E556867B2A'>

    • <optgroup id='E556867B2A'><strike id='E556867B2A'><sup id='E556867B2A'></sup></strike><code id='E556867B2A'></code></optgroup>
        1. <b id='E556867B2A'><label id='E556867B2A'><select id='E556867B2A'><dt id='E556867B2A'><span id='E556867B2A'></span></dt></select></label></b><u id='E556867B2A'></u>
          <i id='E556867B2A'><strike id='E556867B2A'><tt id='E556867B2A'><pre id='E556867B2A'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:comprehensive    Page View:973
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In